HIGHLIGHTS
SUMMARY
(Bhagwat et_al, 2022; Jones et_al, 2022; Liebenberg et_al, 2022)] and to effectively target inherent heterogeneity in infection that results in drug tolerance to prevent treatment failure and subsequent disease relapse (Fox et_al, 1999; Kerantzas and Jacobs, 2017). Antibiotic tolerance is defined as the non-heritable ability of bacteria to survive transient exposure to drugs at concentrations that would otherwise be lethal (Brauner et_al, 2016; Balaban et_al, 2019). Pyrazinamide, a crucial member of the current standard of care regimen, is inactive against Mtb in many in_vitro growth conditions and as a monotherapy in_vivo (Steenken and . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.